N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical Properties

Melting point:

243 °C

Boiling point:

703.1±70.0 °C(Predicted)

Density 

1.250

storage temp. 

Store at -20°C

solubility 

≥25.5 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH

form 

solid

pka

11.95±0.50(Predicted)

N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide Usage And Synthesis

Uses

TG101209 is an effective tyrosine kinase inhibitor of tyrosine kinases JAK2 and JAK3 (janus kinase 2/3), inducing cell arrest and apoptosis in leukemia cell lines.

Definition

ChEBI: TG101209 is a member of the class of pyrimidines that is 5-methylpyrimidine-2,4-diamine in which the amino group at position 2 is substituted by a p-(4-methylpiperazin-1-yl)phenyl group, while that at position 4 is substituted by a m-(tert-butylsulfamoyl)phenyl group. A Janus kinase 2 (JAK2) inhibitor. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a sulfonamide, a member of pyrimidines, a N-alkylpiperazine, a N-arylpiperazine and a secondary amino compound.

Biological Activity

tg101209, a small-molecule identified by structure based design, is a selective inhibitor of janus kinase 2 (jak2) that potently inhibits jak/stat pathway in multiple myeloma (mm) cell lines, such as cell harboring jak2v617f or mplw515l/k mutations which are commonly associated with polycythemia vera (pv) and primary myelofibrosis (pmf) respectively. according to results of multiple studies, it has revealed that tg101209 exhibits a dose and time dependent cyctoxicity, which is associated with inhibited cell cycle progrgression and induced apoptosis, in a wild range of mm cell lines through suppressing the expression of pjak2, pstat3 and bcl-xl and inducing the overexpression of perk and pakt.ramakrishnan v, kimlinger t, haug j, timm m, wellik l, halling t, pardanani a, tefferi a, rajkumar sv, kumar s. tg101209, a novel jak2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for cd45+ myeloma cells. am j hematol. 2010;85(9):675-686.

target

6 nM

N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(936091-14-4)Related Product Information

• TG 100713
• MK-2206 2HCl
• NVP-BSK805
• GDC-0152
• BI 2536
• Fedratinib
• PLX4032
• N,N'-Dimethyl-1,3-propanediamine
• N,N-Dimethylbenzylamine
• N,N-Dimethylbenzamide
• 5-PYRIDIN-4-YL-1H-INDAZOLE
• 3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol
• TG6-10-1
• N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
• SGI 7079
• Gilteritinib
• ABX-1431
• N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine